GSK 2646264

Drug Profile

GSK 2646264

Alternative Names: GSK2646264

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics; Skin disorder therapies
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous lupus erythematosus; Urticaria

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Cutaneous lupus erythematosus in Germany (Topical) (NCT02927457)
  • 05 Oct 2016 GlaxoSmithKline plans a phase I trial for Cutaneous lupus erythematosus in Germany (Topical) (NCT02927457)
  • 30 Aug 2016 Preclinical trials in Cutaneous lupus erythematosus in United Kingdom (Topical) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top